HER2+ Breast Cancer

Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Read a refresh of the top FDA news in breast cancer from April 2026, including an ODAC decision and a breakthrough device designation.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

Catch up on insights into the global development of breast cancer therapies that are making waves around the world.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Neoadjuvant THP demonstrated noninferiority compared with standard TCbHP in patients with stage II or III HER2-positive breast cancer.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

Neoadjuvant T-DXd followed by THP has received conditional approval in China for the treatment of patients with HER2-positive stage II/III breast cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

Response to evorpacept plus zanidatamab was predicted by high levels of CD47 expression in patients with HER2-positive metastatic breast cancer.

Giuseppe Curigliano, MD, PhD, discusses the challenges of treatment sequencing in HER2-positive breast cancer with all the options currently available.

Will the FDA approve T-DXd for HER2-positve early breast cancer with residual disease after HER2-targeted neoadjuvant therapy?